VIVO Meridian Bioscience Inc.

The Klein Law Firm Notifies Investors of Commencement of a Class Action on Behalf of Meridian Bioscience, Inc. Shareholders and a Lead Plaintiff Deadline of January 16, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Meridian Bioscience, Inc. (NASDAQ:VIVO) who purchased shares between March 25, 2016 and July 13, 2017. The action, which was filed in the United States District Court for the Southern District of Ohio, alleges that the Company violated federal securities laws.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Defendant’s lead tests provide inaccurate results; and (ii) as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders have until January 16, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/meridian-bioscience-inc?wire=2.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
12/12/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Meridian Bioscience Inc.

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two new Air-Dryable™ Master Mixes with the launch of its Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These innovative master mixes are designed to develop room-temperature stable molecular diagnostic assays that directly target nucleic acid sequences...

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum. Saliva is a complex fluid containing various enzy...

 PRESS RELEASE

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submi...

 PRESS RELEASE

Meridian Closes Acquisition of BreathTek® Business

Meridian Closes Acquisition of BreathTek® Business CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021. Information on the financial impacts to Meridian’s fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday, August 6, 2021. About Meridian Bioscience, Inc.Meridian is ...

 PRESS RELEASE

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H....

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc. CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationshi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch